

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

TRIAL

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

NCT ID: NCT04424719 Phase: NA Sponsor: Institut Curie Status: Recruiting

SUMMARY

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

KEY ELIGIBILITY CRITERIA

- 1. Patient aged of 18 years or more.
- 2. Patient with uveal melanoma with high metastatic relapse risk defined as :
 - * T2b/c/d ou e T3,
 - * or chromosom 3 or chromosom 8 abnormality by CGH array.
- 3. Completion of treatment of the primary tumor d 2 months.
- 4. Patient able to comply with the schedule of visits and blood samples of the study.
- 5. Signed informed consent form or legal representative.
- 1. Patient without french social insurance.
- 2. Any social, medical or psychological condition making the research process impossible.

ENROLLMENT CONTACT

Marie-Emmanuelle Legrier, PhD

Institut Curie

Paris, France

Phone: 0156245649

Email: drci.promotion@curie.fr

Total sites: 1 | 1 currently recruiting